Presentations and publications

April 10, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies
April 9, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
A versatile platform for efficient affinity optimization of common light chain multi-specific antibodies
March 25, 2019 | AACR Annual Meeting 2019
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers
March 25, 2019 | Keystone Cancer Immunology Symposium
A Novel Class of NK-Cell Engagers Targeting NKp30
November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, eradicates very large tumors by selectively reprogramming the tumor microenvironment without causing hepatic toxicity
November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination
November 10, 2018 | SITC 2018
A novel class of NK cell engagers overcomes CD16A deficiency